Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study

Leukemia & Lymphoma
Guillermo J Ruiz-ArgüellesJosé L Herrera-Garza

Abstract

Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All patients engrafted; median time to achieve an absolute neutrophil count > 0.5 x 10(9)/1 was 12 days (range 0-26), whereas the median time to a platelet count > 20 x 10(9)/1 was 13 days (range 0-26). Patients developed mixed chimerism 15 to 100 (median 30) days after the allograft. The follow-up periods range between 33 and 2670 days (median 450). The median post-transplant overall survival of the patients has not been reached and is above 89 months, whereas the 683 days both overall and progression-free survival is 66%. In 14 grafts (56%) acute GVHD ensued; in 12 cases grades I-II and in 2 cases grade IV which was fatal in both. In 9/19 patients (47%) limited chronic GVHD developed. In 22 cases (88%), the procedure could be completed fully on an outpatient basis. The 100-day and the transplant-related mortality were both 8%. NST appears to be an effective additional therapeutic option for patients with AML in remission...Continue Reading

References

Oct 31, 2000·Current Opinion in Hematology·A J Barrett
Apr 3, 2001·American Journal of Hematology·G J Ruiz-ArgüellesJ C Jaime-Pérez
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Sep 6, 2002·Seminars in Hematology·Richard M Stone
Nov 15, 2002·International Journal of Hematology·Guillermo J Ruiz-Argüelles
Feb 6, 2003·International Journal of Hematology·George E Georges, Rainer Storb
Jul 5, 2003·International Journal of Hematology·Guillermo J Ruiz-Argüelles, David Gómez-Almaguer

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Guillermo J Ruiz-Argüelles
Dec 21, 2006·Hematology·Guillermo J Ruiz-ArgüellesVirginia Reyes-Núñez
Oct 7, 2005·International Journal of Hematology·Guillermo J Ruiz-ArgüellesCésar H Gutiérrez-Aguirrec
Oct 27, 2006·Leukemia & Lymphoma·Guillermo J Ruiz-ArgüellesVirginia Reyes-Nuñez
Oct 6, 2004·Expert Opinion on Biological Therapy·Guillermo J Ruiz-Argüelles, David Gómez-Almaguer
Feb 21, 2006·British Journal of Haematology·Guillermo J Ruiz-Arguelles, David Gomez-Almaguer
Dec 22, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Guillermo J Ruiz-DelgadoGuillermo J Ruiz-Arguelles
Apr 26, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Adalberto ParraGuillermo J Ruiz-Argüelles
Aug 23, 2005·Bone Marrow Transplantation·G J Ruiz-ArgüellesC Manzano
Mar 6, 2019·Journal of Adolescent and Young Adult Oncology·Juan Antonio Flores-JiménezMiguel Ángel Zambrano-Velarde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.